SYNERGY-AI Cancer Trial Finder is a medical platform that matches cancer patients to clinical trials using AI-driven genomic analysis on iOS and Android.
The App DNA
What makes this app unique?
The platform removes the cognitive burden of manually searching global trial databases, providing patients with tailored options that fit their specific medical profile and location.
For Cancer patients, caregivers, and oncology professionals seeking access to clinical trials.
What does it look like?
Key features
Algorithm analyzes patient medical profiles against global trial databases to identify eligibility in real-time.
Human-in-the-loop service connecting matched patients with a professional oncology team for enrollment guidance.
Dedicated interface for oncologists and care teams to submit patient profiles and manage trial referrals.
How much does it cost?
The app is free for patients, with revenue generated through B2B partnerships with pharmaceutical companies and CROs.
Velocity
Dormant developmentopaqueShow more...
The app has reached a zombie state, with no updates recorded in over two years. The last release occurred 757 days ago on Android and 863 days ago on iOS. There is no evidence of active development, feature iteration, or ongoing maintenance for this platform.
Who built it?
Massive Bio Yazilim Dijital Saglik Teknolojileri Anonim Sirketi
1 app tracked · Medical
Explore the full publisher profileUser Sentiment
What do users think recently?
Fresh user feedback skews thrilled. Users appreciate the clinical trial search tool provides a user-friendly interface for families to locate relevant medical studies and personalized trial matching based on location and medical history reduces the need for extensive patient travel.
How are ratings & reviews evolving?
What users say, by theme
- The clinical trial search tool provides a user-friendly interface for families to locate relevant medical studies
- Personalized trial matching based on location and medical history reduces the need for extensive patient travel
22 of 22 recent reviews analyzed · moderate confidence · Thrilled overall
Read the full review analysisUnlock 1 user request, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for SYNERGY-AI Cancer Trial Finder
How's the Medical market?
SYNERGY-AI Cancer Trial Finder maintains a 4.63 average rating across 196 total platform ratings, signaling high user trust in its core matching utility. The 25-month development gap suggests the platform is currently in maintenance mode, limiting its ability to respond to shifting trial data standards.
The rivals identified
The Analyst's Read
Key takeaways for SYNERGY-AI Cancer Trial Finder
Where is it heading?
The clinical trial matching market is consolidating around platforms that offer real-time data integration and frequent algorithmic updates. SYNERGY-AI Cancer Trial Finder remains stable due to its specialized oncology support, but the lack of recent updates leaves it vulnerable to competitors with more aggressive release cadences.
- The 25-month development gap suggests a lack of active investment, which will eventually erode the platform's competitive advantage in trial matching accuracy.
The SWOT
- AI-driven genomic matching replaces manual search friction
- Human-in-the-loop oncology support provides premium differentiation
- Physician referral portal captures professional-led patient volume
- Integration of real-time trial data feeds to improve matching accuracy
Next best moves
Audit the matching algorithm against current trial data because the 25-month update gap risks accuracy decay → maintain trust
The counter-intuitive read
The platform's 25-month silence may be a strategic…
Read the full takeBottom line
SYNERGY-AI Cancer Trial Finder maintains a strong reputation for its core matching utility, but the 25-month development silence risks obsolescence. Validating the algorithm against current trial data would secure the platform's utility while the team addresses the lack of feature iteration.
Unlock 2 critical frictions, 1 market threat and the analyst’s take.
Access the full report for freeSources
- [1] Play Store listing, source
Report last updated